Clinical Trial Record

Return to Clinical Trials

Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda


2023-07-31


2024-12-31


2024-12-31


2357

Study Overview

Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda

Breast cancer incidence is increasing in low- and middle-income countries (LMICs) and breast cancer mortality is high in these regions largely due to late stage diagnoses. This is true in the low-income East African country of Rwanda, where there are no national protocols in place to guide evaluation and referral of breast symptoms at primary health facilities. This study will use quantitative and qualitative methods to examine implementation of the Women's Cancer Early Detection Program (WCEDP) in order to understand optimal strategies to scale and sustain breast cancer early diagnosis in Rwanda and other limited-resource settings. The WCEDP is an adaptation of a prior intervention in Burera District, which focused on building community awareness of breast symptoms, improving clinicians' clinical breast assessment (CBA) skills, and implementing weekly breast clinics at the primary health care center and hospital levels. The Burera intervention was associated with improvements in health care workers' knowledge and skills, increases in care-seeking and receipt of care by women with breast symptoms, and an increase in early-stage breast cancer diagnoses.

Despite the Burera trial's promising results it was clear adaptations would be needed for real-world scaleup. The Burera intervention focused on breast health in isolation, hindering scalability in a limited-resource health system. In addition, it benefited from intensive patient tracking, feasible with the study's resources and implementation in a single district. Rwanda Biomedical Centre (RBC) is now scaling up breast cancer early diagnosis using the Burera training program with two key adaptations. First, in an effort to expand reach and increase efficiency, breast cancer early diagnosis services are offered together with cervical cancer screening in a combined initiative, the Women's Cancer Early Detection Program. The WCEDP combines these services through: 1)Combined provider trainings; 2)Community awareness-raising about both cancers; and 3)Weekly district hospital (DH) and HC clinics for women eligible for cervical cancer screening and CBA. RBC's second adaptation, an effort to facilitate patient tracking and linkage to care at scale, is a tablet-based EMR that allows clinicians to share information across facilities, identify missed visits, and document patient phone calls. These adaptations address priorities of the WHO's Global Breast Cancer Initiative: integrating early diagnosis into primary care services and building systems to facilitate referrals. By examining these adaptations in a real-world setting, this research will contribute to global efforts to identify evidence-based implementation strategies to address breast cancer in LMICs. This study will leverage a longstanding partnership between RBC, Partners In Health (PIH), and Brigham and Women's Hospital (BWH) to pursue the following Specific Aims: Aim 1. Use the RE-AIM framework to examine implementation and impact of Rwanda's adaptation and scale-up of breast cancer early diagnosis within the WCEDP, in 3 districts with 52 HCs. 1a. Evaluate the WCEDP's reach using interrupted time series analysis to examine its impact on the number of patients receiving CBA at HCs, and engagement of older women and those with breast symptoms. 1b. Examine program effectiveness, adoption and implementation by assessing timely linkage to care, loss-to-follow-up, service delivery, and EMR use. Aim 2. Use patient and provider interviews, guided by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework, to elicit contextual factors related to successes and challenges of scaleup, including the WCEDP's fit and acceptability for communities, clinicians, and facilities.

  • Breast Cancer
  • Benign Breast Disease
  • Cervix Cancer
    • 2021P002943

    Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates Results Reporting Dates Study Record Updates

    2022-03-29  

    N/A  

    2025-02-04  

    2022-05-03  

    N/A  

    2025-02-06  

    2022-05-06  

    N/A  

    2025-02  

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    Design Details

    Primary Purpose:
    N/A


    Allocation:
    N/A


    Interventional Model:
    N/A


    Masking:
    N/A


    Arms and Interventions

    Participant Group/ArmIntervention/Treatment
    Primary Outcome MeasuresMeasure DescriptionTime Frame
    Number of patients presenting to health centers for CBA per week (Reach)The primary analysis will be interrupted time series (ITS) Poisson regression to compare the number of patients presenting for CBA to health centers each week in the months before and after initiation of the WCEDP12 months
    Secondary Outcome MeasuresMeasure DescriptionTime Frame
    Age of patients received (Reach)The investigators will examine the median age of individuals presenting before and after WCEDP18 months
    Proportion of patients receiving CBA who had breast symptoms (Reach)Investigators will examine the proportion of patients evaluated at health centers with CBA who had symptoms18 months
    Proportion of patients evaluated with CBA at health centers who also had cervical cancer screening (Reach)Proportion of patients evaluated with CBA at health centers who also had cervical cancer screening (Reach)18 months
    WCEDP Effectiveness - HCsNumber and percentage of women seen at health centers for CBA who are referred to district hospitals (and seen within 1 month of DH visit)12 months
    WCEDP Effectiveness - DHsNumber and percentage of women seen at district hospitals for CBA who are referred to referral facilities (and seen within 1 month of DH visit)12 months
    WCEDP Adoption - CHWsNumber and percentage of community health workers (CHWs) trained12 months
    WCEDP Adoption - CliniciansNumber and percentage of clinicians trained in the program and in electronic medical record12 months
    WCEDP Implementation - ClinicsNumber and percentage of weeks that clinics are held at each health center and district hospital (and the average percentage per district)6 and 12 months
    WCEDP Implementation - CHWsNumber of days/ month that CHWs hold community awareness events or do home visits (and average percentage per district)6 and 12 months
    WCEDP Implementation - electronic medical recordProportion of weeks in which electronic medical record missed-visit reports are run in each district hospital6 and 12 months
    WCEDP Implementation - Phone callsOf patients who have missed district hospital visits, percentage with phone call documented in the electronic medical record6 and 12 months

    Contacts and Locations

    This section provides the contact details for those conducting the study, and information on where this study is being conducted.

    Participation Criteria

    Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

    Ages Eligible for Study:
    ALL

    Sexes Eligible for Study:

    Accepts Healthy Volunteers:
    1

      Inclusion Criteria:

    • All individuals who are evaluated for a breast concern or receive breast cancer screening through implementation of the nationally-led early detection programs

    • Exclusion Criteria:

    • None

    Collaborators and Investigators

    This is where you will find people and organizations involved with this study.

    • Partners in Health
    • Rwanda Biomedical Centre
    • Johns Hopkins University

    • PRINCIPAL_INVESTIGATOR: Lydia Pace, MD, MPH, Brigham and Women's Hospital

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available